Research Topics
Species | B M BrennerSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyB M Brenner
Renal Division, Brigham and Women s Hospital, Boston, MA 02115, USA
N Engl J Med 345:861-9. 2001..We assessed the role of the angiotensin-II-receptor antagonist losartan in patients with type 2 diabetes and nephropathy...
AMGEN International Prize: the history and future of renoprotectionBarry M Brenner
Harvard Medical School, Renal Division, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
Kidney Int 64:1163-8. 2003
Renoprotection by enzyme replacement therapyBarry M Brenner
Harvard Medical School, Boston, Massachusetts, USA
Curr Opin Nephrol Hypertens 13:231-41. 2004
Cardiovascular and renal progression factors in chronic kidney disease: a colloquium in honor of John H. Dirks ISN World Congress of Nephrology Singapore, June 26, 2005Barry M Brenner
Harvard Medical School, Boston, Massachusetts 02115, USA
Kidney Int 68:1411-2. 2005
Remission of renal disease: recounting the challenge, acquiring the goalBarry M Brenner
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115-6195, USA
J Clin Invest 110:1753-8. 2002
Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition aloneM W Taal
Renal Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
J Am Soc Nephrol 12:2051-9. 2001..It is concluded that, in this model, OMA affords greater long-term renoprotection than ENA when doses are adjusted to yield equivalent control of SBP...
Proinflammatory gene expression and macrophage recruitment in the rat remnant kidneyM W Taal
Renal Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115 6110, USA
Kidney Int 58:1664-76. 2000..Macrophage (Mphi) infiltration may contribute to chronic renal injury. We therefore sought to examine the expression of genes associated with Mphi recruitment in the rat remnant kidney model...
Mechanisms underlying renoprotection during renin-angiotensin system blockadeM W Taal
Renal Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Am J Physiol Renal Physiol 280:F343-55. 2001..During renin-angiotensin system inhibition, renoprotection is dependent on control of both SBP and UprV. Incomplete suppression of renal cytokine gene expression may also contribute to CRD progression...
Glomeruli and blood pressure. Less of one, more the other?B M Brenner
Renal Division, Brigham and Women s Hospital, Boston, MA 02115
Am J Hypertens 1:335-47. 1988..This may also account for the susceptibility of subsets of Type I and Type II diabetics to develop overt glomerulopathy...
Current strategies for retarding progression of renal diseaseH S Mackenzie
Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
Am J Kidney Dis 31:161-70. 1998..These interventions form the core of current strategies designed to preserve kidney function in patients with chronic renal disease...
Non-immunologic predictors of chronic renal allograft failure: data from the United Network of Organ SharingG M Chertow
Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Kidney Int Suppl 52:S48-51. 1995..These findings may have important biomedical and health care policy implications...
Antigen-independent determinants of cadaveric kidney transplant failureG M Chertow
Renal Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
JAMA 276:1732-6. 1996..To determine the association of various antigen-independent factors with long-term cadaveric kidney transplant failure...
Renal effects of an acute NaCl load in chronic nitric oxide blockade-induced hypertensive ratsJ C Rodriguez-Perez
Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
J Physiol Biochem 54:127-33. 1998..This observation suggests that in this model of chronic inhibited NO rats, the disposal of an acute sodium load is reached. The existence of a delayed mechanism in renal excretion of Na+ by the chronic NO-blocked rats could be suggested...
Renal mass as a determinant of late allograft outcome: insights from experimental studies in ratsH S Mackenzie
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
Kidney Int Suppl 52:S38-42. 1995..We conclude that mass-related injury processes may play a potentially major and underappreciated role in the pathogenesis of late renal allograft failure...
Glucocorticoids amplify glomerular injury in rats with renal ablationD L Garcia
Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115
Am J Hypertens 1:54-7. 1988..Thus, potent vasodilator glucocorticoids may amplify hemodynamically mediated glomerular injury, whereas control of systemic and glomerular hypertension prevents this undesirable consequence of chronic steroid therapy...
The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: a double-blind, placebo-controlled trial in patients with esrdW F Keane
Department of Medicine, Hennepin County Medical Center, University of Minnesota Medical School, Minneapolis, MN, USA
Am J Kidney Dis 37:S48-53. 2001..It will determine whether treatment with cerivastatin can effectively reduce the significant cardiovascular morbidity and mortality...
'Hypertension' and 'microalbuminuria': the bell tolls for theeJ P Forman
Harvard Medical School, Boston, Massachusetts, USA
Kidney Int 69:22-8. 2006..We propose that the medical community consider abandoning the terms 'hypertension' and 'microalbuminuria' in favor of 'blood pressure-associated' and 'albuminuria-associated' disease...
Therapeutic benefit of converting-enzyme inhibition in progressive renal diseaseS Anderson
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115
Am J Hypertens 1:380S-383S. 1988..These studies suggest that control of glomerular hypertension may be of special benefit to the patient with progressive renal disease...
Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factorO V Sakharova
Renal Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Curr Opin Nephrol Hypertens 10:727-38. 2001..Thus, acting as a downstream mediator of the profibrotic activity of transforming growth factor-beta, connective tissue growth factor may constitute a more specific target for future antifibrotic therapies...
Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertensionR Abdi
Renal Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Transplantation 72:726-9. 2001....
Transcriptional responses to tubule challengesS R Gullans
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
Kidney Int 49:1678-81. 1996..This work highlights the concept that rapid analysis of differential gene expression will enable one to define cellular programs of gene expression involving up- and down-regulation of functionally-related gene families...
Adult hypertension and kidney disease: the role of fetal programmingKambiz Zandi-Nejad
Renal Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Hypertension 47:502-8. 2006....
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studiesAlbert A Carr
Circulatory Disease Center, Augusta, Georgia, USA
Am J Cardiol 96:1530-6. 2005..The beneficial effect of losartan on the reduction of risk for hospitalization for new HF was demonstrated in patients who were at high renal and/or high cardiovascular risk...
Primary and secondary prevention of chronic kidney diseaseKambiz Zandi-Nejad
Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Hypertens 23:1771-6. 2005..The most effective of these interventions is based on the inhibition of the renin-angiotensin system (RAS) and is the main focus of this review...
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) studyZhongxin Zhang
Merck and Co, Inc, P O Box 4, BL 3 4, West Point, PA 19486, USA
J Am Soc Nephrol 16:1775-80. 2005....
Losartan and end-organ protection--lessons from the RENAAL studyPeter R Kowey
Main Line Health Heart Center, Wynnewood, Philadelphia, USA
Clin Cardiol 28:136-42. 2005..Diabetic or renally impaired patients are at high cardiovascular risk, a risk potentially increased in patients with both conditions...
Renoprotective effects of renin-angiotensin-system inhibitorsDick de Zeeuw
Lancet 367:899-900; author reply 900-2. 2006
Losartan: lessons learned from the RENAAL studyShahnaz Shahinfar
Merck and Co, Inc, Whitehouse Station, New Jersey, USA
Expert Opin Pharmacother 7:623-30. 2006..The RENAAL study also provided information that will be valuable to those designing future clinical trials in this patient population. This review highlights key findings from the RENAAL study...
The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathyGeorge W Carides
Merck and Co Inc, Blue Bell, Pennsylvania 19422, USA
Pharmacoeconomics 24:549-58. 2006..4 years). The objective of this study was to project the effect of losartan compared with placebo on the lifetime incidence of ESRD and associated costs (from a US healthcare system perspective)...
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adultsAlberto Ortiz
Dialysis Unit, Universidad Autonoma de Madrid, Fundacion Jimenez Diaz, Avenida Reyes Catolicos 2, 28040 Madrid, Spain
Nat Clin Pract Nephrol 4:327-36. 2008..These organ-specific guidelines could be easier to implement than general guidelines, provided they are used in the context of an overall multisystem care approach...
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathyHans Henrik Parving
Department of Medical Endocrinology, Department 2132, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen Ø, Denmark
J Am Soc Nephrol 19:771-9. 2008..In conclusion, proteinuric type 2 diabetic patients with the D allele of the ACE gene have an unfavorable renal prognosis, which can be mitigated and even improved by losartan...
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL studyAndrew M Tershakovec
Merck Research Laboratories, Merck and Co, Inc, Upper Gwynedd, Pennsylvania, USA
Diabetes Care 31:445-7. 2008..LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria...
Fetal programming of adult kidney disease: cellular and molecular mechanismsDov Hershkovitz
Laboratory of Molecular Medicine, Rambam Health Care Campus, Technion Israel Institute of Technology, Haifa, Israel
Clin J Am Soc Nephrol 2:334-42. 2007
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane
Merck and Co, Inc, Whitehouse Station, New Jersey, USA
Clin J Am Soc Nephrol 1:761-7. 2006..Future trials with a similar patient population and outcomes measures should consider adjusting analyses for baseline risk factors...
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialWouter B A Eijkelkamp
Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
J Am Soc Nephrol 18:1540-6. 2007..Antihypertensive treatment that is aimed at improving renal outcomes in patients with diabetic nephropathy may therefore require a dual strategy, targeting both SBP and albuminuria reduction...
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studiesWouter B A Eijkelkamp
Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
J Hypertens 25:871-6. 2007....
Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetesWolfgang C Winkelmayer
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA
Diabetes Care 29:2210-7. 2006....
Strategies to retard the progression of chronic kidney diseaseKambiz Zandi-Nejad
Renal Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
Med Clin North Am 89:489-509. 2005..The increasing incidence, prevalence, and costs of ESRD are major national health care concerns; interventions that may prevent or slow the progression of CKD towards ESRD are extremely important and the focus of this article...
Preventing microalbuminuria in type 2 diabetesKambiz Zandi-Nejad
N Engl J Med 352:833-4; author reply 833-4. 2005
Combination ACEI and ARB therapy: additional benefit in renoprotection?Maarten W Taal
Renal Unit, Derby City General Hospital, Derby DE22 3NE, UK
Curr Opin Nephrol Hypertens 11:377-81. 2002..In the light of the persisting need for treatments that afford more effective renoprotection, this Special Commentary examines available experimental and clinical evidence in support of this hypothesis...
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluationWilliam H Herman
Departments of Internal Medicine and Epidemiology, University of Michigan Health System, Ann Arbor, Michigan 48109 0354, USA
Diabetes Care 26:683-7. 2003..To evaluate the within-trial effect of losartan and conventional antihypertensive therapy (CT) compared with placebo and CT on the economic cost associated with end-stage renal disease (ESRD)...
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane
Department of Medicine, Hennepin County Medical Center, University of Minnesota Medical School, Minneapolis, Minnesota, USA
Kidney Int 63:1499-507. 2003..We examined the risk factors that predict loss of kidney function (doubling of serum creatinine) or ESRD (dialysis or transplantation) in patients with type 2 diabetes in whom blood pressure was controlled...
Analysis of metabolic parameters as predictors of risk in the RENAAL studyGerald B Appel
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
Diabetes Care 26:1402-7. 2003..CONCLUSIONS: Overall, losartan was well tolerated by patients with type 2 diabetes and nephropathy and was associated with a favorable effect on the metabolic profile of this population...
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL studyGeorge L Bakris
Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Rush Medical College, Chicago, IL 60612, USA
Arch Intern Med 163:1555-65. 2003..Clinical trials of nephropathy in people with type 2 diabetes mellitus have not examined the effects of systolic blood pressure (SBP) or pulse pressure (PP) on the time to end-stage renal disease (ESRD) or death...
Impact of the supplementation of kidney mass on blood pressure and progression of kidney diseaseMai Ots
Renal Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, USA
Nephrol Dial Transplant 19:337-41. 2004..To test the hypothesis that nephron mass is an independent determinant of arterial pressure, the effects of augmenting renal mass by isograft transplantation were studied in the model of secondary hypertension...
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL StudyJuliana C N Chan
Department of Medicine and Therapeutics, The Chinese University Hong Kong, The Prince of Wales Hospital, Hong Kong, Shatin, China
Diabetes Care 27:874-9. 2004..In this subgroup analysis, we examined the characteristics, response, and adherence to treatment of the Asian population, as well as their baseline predictors of risk of renal end points...
Regarding: "Management of glomerular proteinuria: a commentary"Barry M Brenner
Department of Medicine, Renal Division, Brigham and Women's Hospital, Boston, Massachusetts, USA
J Am Soc Nephrol 15:1354-5; discussion 1356-7. 2004
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial resultsGiuseppe Remuzzi
Clinical Research Center for Rare Diseases Aldo e Cele Dacc, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
J Am Soc Nephrol 15:3117-25. 2004..Angiotensin II antagonism is a suitable and well-tolerated treatment for individuals with type 2 diabetes even with GFR levels approaching renal replacement therapy...
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAALDick de Zeeuw
Department of Clinical Pharmacology, University Medical Center Groningen, Groningen, The Netherlands
Kidney Int 65:2309-20. 2004....
The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathyWilson Y S Leung
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, N.T, Hong Kong, SAR
Nephrol Dial Transplant 19:2519-25. 2004....
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathyDick de Zeeuw
Department of Clinical Pharmacology, Groningen University Medical Center, Ant Deusinglaan 1, 9713 AV Groningen, Netherlands
Circulation 110:921-7. 2004..Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention...
Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathyAnupama Mohanram
UT Southwestern Medical Center, Dallas, Texas 75390-8856, USA
Kidney Int 66:1131-8. 2004..CONCLUSION: Our data suggest that even mild anemia, Hb <13.8 g/dL increases risk for progression to ESRD. Hemoglobin is an independent risk factor for progression of nephropathy to ESRD in type 2 diabetes...
Defining renal riskMaarten W Taal
Curr Opin Nephrol Hypertens 16:554-6. 2007
From secondary to primary prevention of progressive renal disease: the case for screening for albuminuriaPaul E de Jong
University Hospital Groningen, Groningen Institute for Drug Exploration, Groningen, The Netherlands
Kidney Int 66:2109-18. 2004....
Dialysis delayed is death prevented: a clinical perspective on the RENAAL studyMerlin C Thomas
The Baker Medical Research Institute, Victoria, Australia
Kidney Int 63:1577-9. 2003
Retarding the progression of renal diseaseBarry M Brenner
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Kidney Int 64:370-8. 2003
Impact of renin angiotensin system blockade on renal function in health and disease: an end or a beginning?Reza Abdi
Renal Division, Brigham and Women s Hospital, Boston, MA 02115 6392, USA
Semin Nephrol 24:141-6. 2004..Numerous animal studies as well as recent clinical trials indicate that blockade of the renin angiotensin system effectively retards progression of nephropathy from diverse origins...
Chemokine receptor polymorphism and risk of acute rejection in human renal transplantationReza Abdi
Renal Division, Brigham and Women s Hospital, Boston, Massachesetts, USA
J Am Soc Nephrol 13:754-8. 2002..20; P = 0.032) and homozygosity for the 59029-A allele (OR, 0.26; P = 0.027). It was concluded that the risk of acute rejection in renal transplantation is associated with genetic variation in the chemokine receptors CCR2 and CCR5...
